💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Carfilzomib

CHEMBL451887 Phase 4 معتمد Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
719.9 g/mol
LogP
4.7
Phase
4

A proteasome inhibitor that selectively and irreversibly blocks the activity of the proteasome, disrupting protein degradation pathways that cancer cells depend on for survival. It is used intravenously to treat relapsed or refractory multiple myeloma. Cardiovascular monitoring is important during treatment due to the risk of cardiac complications.

الوزن الجزيئي

719,9000 g/mol

LogP

4,70

TPSA

158,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Hypertension Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

آلية العمل

Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

                

                

                
                

                    
InChI

                    
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C40H57N5O7

                    

                    
                    

                        
HBD / HBA

                        
4 / 8

                    

                    
                    

                        
الروابط القابلة للدوران

                        
20

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A proteasome inhibitor that selectively and irreversibly blocks the activity of the proteasome, disrupting protein degradation pathways that cancer cells depend on for survival. It is used intravenously to treat relapsed or refractory multiple myeloma. Cardiovascular monitoring is important during treatment due to the risk of cardiac complications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Carfilzomib is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL451887.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11556711.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.